Convergentgenomics
1 known investors
Convergent Genomics develops UroAmp, a non-invasive genomic urine test for detecting and monitoring bladder cancer using liquid biopsy and next-generation sequencing technology. The company serves clinicians and patients seeking earlier cancer detection and recurrence monitoring.
BiotechDigital HealthMedical Devices